



HUTCHISON CHINA MEDITECH LIMITED

### Director's Share Dealing

**London: Monday, March 19, 2018:** Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) has received notification that Dr Dan Eldar, Non-executive Director, purchased a total of 2,768 American Depositary Shares of the Company ("ADSs", each representing one half of one ordinary share of US\$1.00 each in the capital of Chi-Med) on March 14, 2018 at an average price of US\$36.11 per ADS.

Following the above purchase, Dr Eldar is interested in 8,993 ADSs and 1,900 Ordinary Shares, representing approximately 0.0096% of the current issued share capital of Chi-Med.

The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.

<b>1</b>	<b>Details of the person discharging managerial responsibilities/person closely associated</b>							
a)	Name	Dr Dan Eldar						
<b>2</b>	<b>Reason for the notification</b>							
a)	Position/status	Non-executive Director						
b)	Initial notification/Amendment	Initial notification						
<b>3</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>							
a)	Name	Hutchison China MediTech Limited						
b)	LEI	2138006X34YDQ6OBYE79						
<b>4</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>							
a)	Description of the financial instrument, type of instrument Identification code	ADS each representing one half of one Ordinary Share of US\$1.00  ADS ISIN: US44842L1035						
b)	Nature of the transaction	Acquisition of 2,768 ADSs on March 14, 2018 at an average price of US\$36.11 per ADS						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>US\$36.12</td> <td>2,700</td> </tr> <tr> <td>US\$35.74</td> <td>68</td> </tr> </tbody> </table>	Price(s)	Volume(s)	US\$36.12	2,700	US\$35.74	68
Price(s)	Volume(s)							
US\$36.12	2,700							
US\$35.74	68							

d)	Aggregated information — Aggregated volume — Price	N/A
e)	Date of the transaction	2018-03-14
f)	Place of the transaction	Nasdaq Stock Market

## About Chi-Med

Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.

Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 1). For more information, please visit: [www.chi-med.com](http://www.chi-med.com).

## CONTACTS

### Investor Enquiries

Mark Lee, Senior Vice President, Corporate Finance & Development +852 2121 8200

### U.K. & International Media Enquiries

Anthony Carlisle, Citigate Dewe Rogerson +44 7973 611 888 (Mobile) [anthony.carlisle@cdrconsultancy.co.uk](mailto:anthony.carlisle@cdrconsultancy.co.uk)

### U.S. Based Media Enquiries

Brad Miles, BMC Communications +1 (917) 570 7340 (Mobile) [bmiles@bmccommunications.com](mailto:bmiles@bmccommunications.com)  
Susan Duffy, BMC Communications +1 (917) 499 8887 (Mobile) [sduffy@bmccommunications.com](mailto:sduffy@bmccommunications.com)

### Investor Relations

Matt Beck, The Trout Group +1 (917) 415 1750 (Mobile) [mbeck@troutgroup.com](mailto:mbeck@troutgroup.com)  
David Dible, Citigate Dewe Rogerson +44 7967 566 919 (Mobile) [david.dible@citigatedewerogerson.com](mailto:david.dible@citigatedewerogerson.com)

### Panmure Gordon (UK) Limited

Richard Gray / Andrew Potts +44 (20) 7886 2500